Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jason Dacruz

Physician Assistant Farmington, CT Physician Assistant

NPI 1417034786 CMS profile 10773172

270 Farmington Ave, Suite 102, Farmington, CT 06032

Open in the dashboard

General payments

$6,188

101 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Dacruz of Farmington, CT is reported in the CMS Open Payments database as having received $6,188 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,311 13
2024 General $1,205 9
2023 General $1,923 51
2022 General $187 24
2021 General $1,562 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Dacruz
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jason Dacruz were reported at $1,311. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jason Dacruz Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,562 $132 $37–$438 $132
2022 $187 $155 $48–$522 $149
2023 $1,923 $167 $52–$557 $160
2024 $1,205 $178 $55–$600 $164
2025 $1,311 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Centinel Spine, LLC $2,336 8 payments
  2. RTI Surgical, Inc. $1,389 2 payments
  3. Stryker Corporation $1,042 4 payments
  4. Globus Medical, Inc. $405 61 payments
  5. BIOTRONIK NRO, Inc. $328 9 payments
  6. Abbott Laboratories $158 1 payment
  7. MML US, Inc. $156 2 payments
  8. Medtronic, Inc. $118 3 payments
  9. DePuy Synthes Sales Inc. $57 2 payments
  10. Dilon Technologies, Inc. $43 1 payment
  11. Other $157 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $3,246 10 payments
  2. Food and Beverage $1,667 90 payments
  3. Consulting Fee $1,275 1 payment
Products named General payments · program years 2021–2025
  1. SIMMETRY IMPLANT, 12.5MM X 50MM $1,389 2 payments
  2. PRODISC C VIVO $1,311 5 payments
  3. N/A $1,042 4 payments
  4. PRODISC L $1,025 3 payments
  5. Octrode SCS Leads $158 1 payment
  6. Prospera Not Applicable $158 5 payments
  7. ReActiv8 $156 2 payments
  8. Prospera Not Applicable $122 3 payments
  9. MAZOR X SYSTEM $73 2 payments
  10. RISE-L $50 3 payments
  11. Other $698 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,696

Median for Physician Assistant: 241

Drug cost

$17,750

Median for Physician Assistant: $4,110

Branded share of claims

12.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 190 $2,219
Methocarbamol Generic 126 $1,946
Oxycodone Hcl Generic 194 $1,914
Tramadol Hcl Generic 405 $1,732
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 106 $1,667
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 25 $1,287
Lidocaine Generic 20 $1,239
Baclofen Generic 117 $1,116
Acetaminophen-Codeine Acetaminophen With Codeine Brand 67 $834
Etodolac Generic 25 $672

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$27,917

Of which drugs: $246

Medicare patients

252

Average age 74

Services billed

698

135 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 69%
Diabetes 27%
Ischemic heart disease 27%
Depression 26%
Chronic kidney disease 22%
Atrial fibrillation 19%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 11 48 $246

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record